Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | WS-CART-CS1 |
Synonyms | |
Therapy Description |
WS-CART-CS1 are T-lymphocytes engineered to express a chimeric antigen receptor (CAR) targeting the distal V domain of SLAMF7 (CS1), which potentially induce killing of SLAMF7 (CS1)-expressing tumor cells and inhibit tumor growth (PMID: 35422095). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
WS-CART-CS1 | CS1-CAR-T | WS-CART-CS1 are T-lymphocytes engineered to express a chimeric antigen receptor (CAR) targeting the distal V domain of SLAMF7 (CS1), which potentially induce killing of SLAMF7 (CS1)-expressing tumor cells and inhibit tumor growth (PMID: 35422095). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT06185751 | Phase I | Cyclophosphamide + Fludarabine WS-CART-CS1 | Safety and Efficacy of CS1 CAR-T (WS-CART-CS1) in Subjects With Multiple Myeloma | Recruiting | USA | 0 |